December 24, 2013 | The Israeli Office of the Chief Scientist (OCS) has granted biomed company Cell Cure Neurosciences (a subsidiary of Bio Time) NIS 6.1 million. Cell Cure will use the funds to develop its OpRegen product, a cell-based treatment for age-related macular degeneration.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments